ImmunityBio's Bladder Cancer Treatment Gains Momentum in 2025

In 2025, ImmunityBio, Inc. (NASDAQ:IBRX) is making significant strides in the healthcare industry as one of the best-performing biotech stocks. The company, a clinical-stage biotech developing advanced immunotherapies and vaccines, has recently achieved a key milestone with the FDA approval of its immunotherapy drug ANKTIVA for bladder cancer.

ANKTIVA, designated a Breakthrough Therapy, is now expanding its clinical use, with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher risk of bladder cancer. This expansion is a testament to the drug's growing adoption and its potential to address an underserved cancer indication.

Financially, ImmunityBio reported a 60% revenue growth in Q2 2025, reaching $26.4 million, and a year-to-date total of approximately $43 million. This growth is driven by the increased commercial momentum post-ANKTIVA's approval and is further supported by an $80 million capital raise in July 2025, which will fuel the company's ongoing development and expansion efforts.

As ImmunityBio transitions from a clinical-stage biotech to a commercial-stage company, the success of ANKTIVA, including its recent UK regulatory approval for use in combination with BCG, positions the company for continued growth and impact in the healthcare sector.